金属- ((环形米诺碳) 复合体表现出对三阴性乳腺癌的纳米分子抗增殖活性
Svetlana A Katkova1, Alexander S Bunev2, Rovshan E Gasanov2
1Saint Petersburg State University, 7/9 Universitetskaya Nab., St. Petersburg, 199034, Russian Federation.
Chemistry (Weinheim an der Bergstrasse, Germany)
|February 16, 2024
概括
新的有机金属抗癌药物,包括和,显示出对癌细胞的高强度和选择性. 这些新型化合物在临床前模型中比西斯更有效.
科学领域:
- 有机金属化学 有机金属化学
- 药用化学 医学化学
- 癌症生物学 癌症生物学
背景情况:
- 开发新型抗癌药物对于克服现有治疗方法 (如思) 的局限性至关重要.
- 有机金属复合物为癌症治疗提供独特的作用机制.
- 环形米诺碳联体为基于金属的药物提供了稳定的支架.
研究的目的:
- 合成和描述新型水解稳定的 (PdII) 和 (PtII) 复合物.
- 评估这些复合体对各种癌症细胞系的抗增殖活性和选择性.
- 在临床前癌症模型中评估主要候选药物的体内疗效.
主要方法:
- 合成和结构性表征Pd(II) 和Pt(II) 复合物与非循环性钻石碳化合物联体.
- 在体外抗增殖试验中,使用人类癌细胞系和正常纤维细胞的小组进行抗增殖试验.
- 在小鼠中使用MDA-MB-231异种移植瘤模型的体内疗效研究.
主要成果:
- 新型Pd(II) 和Pt(II) 复合体显示出纳米分子抗增殖活性 (IC50 0.070.81 μM).
- 这些复合体对癌细胞具有显著的选择性,高达300倍,比正常纤维细胞更强.
- 这种主要候选药物在体外显示出比西斯更强的功效300倍,在体内显示出在减少瘤生长方面更强的功效.
结论:
- 含有非循环米诺碳联体的水解稳定的Pd (II) 和Pt (II) 复合物代表了一个有前途的新类有机金属抗癌剂.
- 化合物表现出强大和选择性的抗癌活性,在临床前评估中表现优于思.
- 这些发现支持进一步开发这些新型金属基化合物作为癌症治疗的潜在治疗剂.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K


